Skip to main content
Galecto, Inc. logo

Galecto, Inc. — Investor Relations & Filings

Ticker · GLTO ISIN · US36322Q1076 US Manufacturing
Filings indexed 310 across all filing types
Latest filing 2026-05-04 Regulatory Filings
Country US United States of America
Listing US GLTO

About Galecto, Inc.

https://galecto.com/

Galecto, Inc. is a clinical-stage biotechnology company that develops novel small molecule therapeutics for cancer and severe liver diseases. The company leverages its expertise in galectin biology to create product candidates that modulate central disease pathways. Its pipeline focuses on inhibitors of key proteins such as galectin-3 and LOXL2, which are implicated in fibrosis and cancer progression. In October 2024, Galecto expanded its oncology portfolio by acquiring GB3226, a novel dual ENL-YEATS and FLT3 inhibitor for the treatment of multiple genetic subsets of acute myeloid leukemia (AML). The company's research also targets other cancers, including melanoma, head and neck squamous cell carcinoma (HNSCC), and hepatocellular carcinoma (HCC). Galecto's mission is to develop safe and effective treatments that significantly improve patient quality of life.

Recent filings

Filing Released Lang Actions
8-K - Damora Therapeutics, Inc. (0001800315) (Filer)
Regulatory Filings
2026-05-04 English
8-K - Damora Therapeutics, Inc. (0001800315) (Filer)
Regulatory Filings
2026-04-20 English
4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
Director's Dealing
2026-03-25 English
4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
Director's Dealing
2026-03-25 English
4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
Director's Dealing
2026-03-25 English
4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
Director's Dealing
2026-03-25 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.